Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

62.88 -1.61 (-2.50%)
Official Closing Price Updated: 4:10 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility. 
Via Benzinga
Topics Economy
Exposures Product Safety Supply Chain
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential. 
Via Benzinga
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch
Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition. 
Via Benzinga
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
Exposures Product Safety Supply Chain
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
Recent Filing Shows That Rep. Scott Franklin Bought Over $16K Worth of Novo Nordisk Stock
Via Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
Is Novo Nordisk Gaining or Losing Market Support?
Via Benzinga
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite? 
Via MarketBeat
Exposures Product Safety
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Exposures Political
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries. 
Via Benzinga
Topics Government
Exposures Political
Retail Traders Prefer Novo Nordisk To Eli Lilly After Medicare Shuts Door On Obesity Drug Coverage — But There's More
However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population 
Via Stocktwits
Topics Government World Trade
Exposures Political Tariff
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected. 
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): good value for what you're paying.
NOVO-NORDISK A/S-SPONS ADR may be an undervalued stock option. NYSE:NVO retains a strong financial foundation and an attractive price tag. 
Via Chartmill
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. 
Via Investor's Business Daily
Topics Government
Exposures Political
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results. 
Via Benzinga
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%. 
Via Benzinga
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver. 
Via MarketBeat
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket. 
Via Benzinga
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting... 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.